U-LABA/ICS Effects on Exercise Performance, Formoterol

• Status: Not yet recruiting
• Trial end date: 2025-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the project is to investigate exercise performance in well-trained individuals in a crossover design following varying degrees of bronchodilation/constriction intervention using current standard procedures.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Morten Hostrup, PhD
• Treatments: Budesonide, Formoterol Fumarate Drug Combination; Formoterol Fumarate; Mannitol

Criteria

Inclusion Criteria:

• Age 18-45

• Physically active >5 hours a week

• Maximum oxygen uptake classified as high or very high

Exclusion Criteria:

• Diagnosed with severe asthma and been in treatment with long-acting beta2-agonist/corticosteroid

• ECG abnormality

• FEV1/FVC ratio < 0,7 determined with spirometry

• Chronic illness determined to be a potential risk for participant during the study

• In chronic treatments with medication that may interfere with study results

• Pregnancy

• Smoker

• Blood donation during the past 3 months